MET and lung carcinoma: Our findings suggest that detection methods for identification of MET exon 14 skipping mutations should be selected cautiously in the future, since MET protein overexpression is not always observed in patients with MET exon 14 skipping mutation cases; MET protein overexpression is far more prevalent than MET exon 14 skipping mutations in lung cancers.